Sicombyl

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sicombyl

What is Sicombyl?

Sicombyl is a fixed-dose combination topical medication developed for the treatment of inflammatory skin conditions, specifically plaque psoriasis. It combines two active pharmacological agents with distinct mechanisms of action to address both the inflammatory and proliferative aspects of the disease.

Composition and Active Ingredients

The medication consists of a corticosteroid and a vitamin D analogue formulated together in a single topical vehicle:

  • Betamethasone dipropionate: A potent synthetic corticosteroid. It works by suppressing the immune response and reducing the production of inflammatory mediators in the skin. This helps to alleviate redness, swelling, and itching.
  • Calcipotriol: A synthetic derivative of vitamin D3. It functions by regulating cell growth and differentiation. In patients with psoriasis, skin cells (keratinocytes) reproduce at an abnormally fast rate; calcipotriol helps to slow down this overproduction and encourages more normal skin cell development.

Therapeutic Intent

The primary objective of Sicombyl is to manage the symptoms of stable plaque psoriasis. By utilizing two different pathways—anti-inflammation and cell-cycle regulation—the combination therapy aims to:

  • Flatten thickened psoriatic plaques.
  • Reduce the scaling and shedding of the skin.
  • Minimize the localized erythema (redness) associated with skin lesions.

This dual-action approach is intended to provide more comprehensive management of the condition than either ingredient used in isolation, focusing on stabilizing the affected skin areas and improving the overall appearance of the skin surface.

What side effects are possible with Sicombyl?

Possible Side Effects and Safety Information: Sicombyl

Sicombyl is a drug containing Hymecromone (4-Methylumbelliferone), an active ingredient with choleretic and spasmolytic properties used to treat biliary tract disorders.

General Safety Profile

Hymecromone is generally considered well-tolerated based on clinical use and studies. Reported side effects are typically mild and transient.

Possible Side Effects

The most commonly reported side effects involve the gastrointestinal system:

  • Diarrhea
  • Abdominal discomfort or pain
  • Nausea
  • Bloating

Hypersensitivity reactions (allergic reactions) are possible, though rare. Signs of a severe allergic reaction may include rash, itching, swelling of the face, lips, or tongue, and difficulty breathing, requiring immediate medical attention.

Contraindications and Precautions

Sicombyl is contraindicated in patients with:

  • Hypersensitivity to Hymecromone or any of the excipients.
  • Acute obstruction of the bile ducts.
  • Acute cholecystitis (inflammation of the gallbladder).
Condition Recommendation
Gallstones (Cholelithiasis) May be used, as it is not typically contraindicated.
Pregnancy/Lactation Use with caution, only if clearly necessary, and after medical consultation.

Patients should consult a healthcare professional if they experience persistent or severe side effects, or if their symptoms worsen.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Sicombyl (Sodium Salicylate) is associated with a specific toxic syndrome documented in regulatory texts, known as salicylism. Initial manifestations often include Tinnitus, Vomiting, Hyperventilation, Deafness, and Lethargy. Severe outcomes, cited in official documentation, involve life-threatening effects on the Central Nervous System (e.g., Seizures, Cerebral Edema) and the Metabolic System, potentially leading to profound Metabolic Acidosis and Respiratory Failure.


Regulators mandate that individuals seek immediate medical attention for the presence of these specific symptoms or if a toxic dose, such as an acute ingestion over 150 mg/kg, is suspected. Emergency referral is also required for all cases involving self-harm. Furthermore, regulatory guidance notes that patients under ten years or over 70 carry an increased risk of toxicity and may require enhanced elimination procedures sooner.


The management of overdose is primarily symptomatic and supportive, as no specific antidote is known in official labeling. Officially described procedures for severe toxicity include the administration of Activated Charcoal, the use of Urinary Alkalinization with sodium bicarbonate, and Hemodialysis. Monitoring requires continuous checks of Acid-Base Status, Serum Electrolytes, and Salicylate Plasma Concentration until the patient is stable and asymptomatic for a minimum of six hours.

Therapeutic Uses of Sicombyl

Sicombyl is used for the management of symptoms related to physical discomfort and states of systemic imbalance.

What Sicombyl Treats: Main Uses and Benefits

Sicombyl may be part of symptomatic management for symptoms related to physical discomfort and inflammatory or irritative states. It contributes to easing the overall symptom load in conditions presenting with systemic or localized discomfort. This is relevant in contexts involving heightened systemic burden, applied when symptoms create noticeable functional strain or interfere with daily comfort.

The medication is considered relevant in clinical settings marked by elevated body temperature (fever), a symptom associated with acute or episodic changes. It is often used when symptoms intensify and supportive relief is needed, helpful in situations requiring additional symptomatic assistance to address symptom clusters that may appear suddenly. It may assist with maintaining functional stability during difficult episodes by easing distress.

Sicombyl is applied across domains where additional symptomatic support is needed, including conditions characterized by periods of heightened symptoms associated with chronic conditions like Osteoarthritis, Rheumatoid Arthritis, Gout, and Rheumatic Fever. It is used in areas where short-term symptom management is appropriate, providing support that helps ease the overall symptom burden.


Quick Fact: Supportive Management for Pain, Inflammation, and Fever Symptoms

Regulatory References

  1. NIH MeSH Overview of Sodium Salicylate

Eligibility and Restrictions for Use

Who Can and Cannot Use Sicombyl?

The population eligibility for Sicombyl (Sodium Salicylate) is determined by official regulatory labeling, defining groups for whom use is strictly prohibited or restricted due to classification as a salicylate and NSAID.

Absolute Contraindications

Use is strictly contraindicated for several populations:

  • Patients with known hypersensitivity to Sodium Salicylate, aspirin, or any other NSAID, including those with a history of aspirin-sensitive asthma.
  • Pregnant women starting at 30 weeks gestation and later (Third Trimester).
  • Children and adolescents under 16 years for general use, due to the established risk of Reye's syndrome in the context of viral illness.
  • Patients with severe hepatic impairment, severe renal impairment, severe heart failure, or those in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Conditional and Restricted Use

Official labeling requires caution and monitoring for specific groups, including elderly patients, who may require a lower dose, and patients with a history of gastrointestinal bleeding or hypertension. Use is generally not recommended during breastfeeding/lactation due to the drug's excretion into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sicombyl, containing the active ingredient Sodium Salicylate, possesses an official interaction profile consistent with its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Documented Pharmacodynamic and Toxicity Interactions

Co-administration with other Salicylates or NSAIDs is restricted due to the documented potential for additive gastrointestinal toxicity, including the risk of bleeding and ulceration. The official profile also cautions against the use of Sicombyl with drugs that interfere with hemostasis (e.g., Warfarin, SSRIs), which further increases the risk of hemorrhage. Pharmacodynamically, the drug may diminish the therapeutic effect of certain ACE Inhibitors, ARBs, and Diuretics.

Documented Exposure-Altering Interactions

Regulatory documents state that Sicombyl can increase the serum concentration of co-administered medicines, notably Digoxin and high-dose Methotrexate, attributed to altered elimination. Conversely, co-administration with Corticosteroids may increase the plasma clearance of salicylate, potentially leading to lower systemic exposure.

Restrictions and Substance Interactions

Use is formally restricted in certain populations, specifically children and teenagers with suspected viral infections due to the risk of Reye's syndrome. Furthermore, the label advises on the use of alcohol (ethanol), which is documented to increase the risk of gastrointestinal blood loss. The interaction structure necessitates careful consideration of concomitant medications to avoid officially documented risks.

Mechanism of Action

How Sicombyl Works

Sicombyl's mechanism is driven by influencing physiological signaling via a dual pathway system, acting via both enzyme inhibition and genetic signaling to produce its physiological effects.


Reversible Inhibition of Cyclooxygenase (COX) Enzymes

This domain covers the drug's primary action: the reversible inhibition of COX enzymes ( COX-1 and COX-2). By blocking these enzymes, the drug modifies an early molecular step in the Arachidonic Acid Cascade, leading to a significant reduction in prostaglandin synthesis systemically. This mechanism influences the molecular steps underlying nociceptive signaling and central thermoregulation.


Suppression of Inflammatory Gene Signals

The second domain involves modulating the production of inflammatory mediators at the genetic level. The drug acts as a Suppressor of transcription factors, notably Nuclear Factor-kappa B ( NF-kappa B), which are responsible for instructing cells to synthesize pro-inflammatory proteins. This mechanism reduces the generation of excessive inflammatory mediators, thereby altering the dynamics of inflammatory pathways.


Mechanistic Constraint by Reversible Action

This domain addresses the binding kinetics, where the interaction with COX enzymes is reversible, not permanent. This characteristic means the modulation of the targeted pathway is strictly concentration-dependent. The resulting physiological effect is maintained only as long as the drug concentration is adequate at the target site, producing physiological adjustments that reflect the drug's short-term profile.

Dosage and Administration Information

How to Use Sicombyl

The administration of Sicombyl, a salicylate derivative, follows established protocols concerning the route, dose, and required preparation. The medicine is supplied as a Powder or Oral Solution and is intended exclusively for the oral route of administration.


Administration Protocol and Dosing

Sicombyl is taken with food or a full glass of liquid (approximately 240 mL) of water or milk to help manage potential gastrointestinal irritation. The powdered or concentrated oral solution forms require dilution or dissolution with an appropriate liquid before ingestion; concentrated solution must not be administered directly.

Dosing is structured based on the intended purpose. For analgesic or antipyretic use, adults typically take 325 mg to 650 mg per dose as needed. For the anti-inflammatory management of conditions such as chronic arthritis, the total daily dose is higher, generally ranging from 3.6 g to 5.4 g. This amount is administered in divided doses multiple times per day to ensure stable levels in the bloodstream.


Duration and Special Considerations

The duration of use is determined by the treatment goal. For the management of acute symptoms, use is limited to a short duration (e.g., no more than 10 days in adults) before medical evaluation is necessary. For chronic management, long-term administration is utilized.

Certain considerations apply to specific populations. Dosing for older adults may require a lower total daily amount. Furthermore, the use of salicylate preparations is restricted and generally not recommended in children under 3 years old.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sicombyl (Sodium Salicylate)


Evidence for Use in Acute Rheumatic Fever Symptoms

Research exploring the use of salicylates, including Sodium Salicylate, for Acute Rheumatic Fever (ARF) symptoms was evaluated in historical clinical series and retrospective analyses. These studies monitored outcomes related to physical discomfort, particularly the acute, disruptive episodes of fever and joint pain. Findings describe patterns observed in the studies where research highlights changes measured during the study period, including measures of fever and joint discomfort. However, studies did not report evidence of reliably preventing or altering the development of long-term cardiac damage. Existing studies provide limited insight into whether Sodium Salicylate may alter the progression to rheumatic valve disease.


Evidence for Use in Chronic Inflammatory Conditions

Research has explored the use of Sodium Salicylate in conditions involving periods of heightened symptoms, specifically Rheumatoid Arthritis (RA) and Osteoarthritis (OA). For both conditions, research examined patient-reported outcomes describing perceived discomfort and functional changes. Some short-term trials reported that the compound was associated with measured changes. However, the studies conducted for Rheumatoid Arthritis are largely dated and findings were often based on older study designs. For Osteoarthritis, research provides insight into short-term changes, and findings were mixed across studies. Certainty remains low regarding its role compared to newer therapeutic options.


What Remains Uncertain About the Research for Sicombyl

Evidence quality varies across studies, with many trials for chronic conditions being older, historical research, which complicates its comparison to current medical standards. Comparative evidence against many modern treatments is lacking, and certainty remains low in certain areas. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Specifically, research does not determine the ability of Sodium Salicylate to alter or prevent long-term disease progression in chronic inflammatory conditions.

Key Studies & References

  1. Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetylsalicylic acid (aspirin) in rheumatoid arthritis
  2. Topical salicylates useful for acute pain but show poor efficacy in chronic arthritic pain (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Sicombyl (FAQ)

Q: Can older adults safely use Sicombyl?

A: Official product information advises caution when Sicombyl is used by older adults. This is because they may have a higher risk of experiencing side effects common to NSAIDs, such as problems with the kidneys or gastrointestinal system. Caution and medical monitoring may be necessary, and official guidance suggests that a lower dose may be needed.

Q: Is Sicombyl safe to use for people with kidney issues?

A: Regulatory warnings state that Sicombyl should not be used in cases of severe renal impairment (severe kidney problems). Like other NSAIDs, the medicine is associated with a risk of kidney issues, including acute renal failure. Consultation with a healthcare provider is essential if you have any degree of kidney impairment.

Q: Can people with liver problems take Sicombyl?

A: The official label strictly contraindicates the use of Sicombyl for people with severe hepatic impairment (severe liver problems). Caution is generally advised, and official guidance for severe impairment is to avoid use.

Q: Can pregnant women or breastfeeding mothers use Sicombyl?

A: Official regulatory documents advise against using Sicombyl from the 30th week of pregnancy onward due to potential risks to the fetus. Use is generally advised to be avoided starting at 20 weeks of pregnancy. For breastfeeding, use is typically not recommended because the medicine’s active ingredients can pass into human milk. Consultation with a healthcare provider is recommended.

Q: Do I need to take Sicombyl with food, or can I take it on an empty stomach?

A: Official instructions indicate Sicombyl should be taken with food or a full glass of liquid, such as water or milk. This is specifically recommended to help reduce the risk of irritating the gastrointestinal system and minimize the potential for stomach bleeding.

Q: What should I do if a side effect from Sicombyl seems to be getting worse?

A: Official warnings advise that serious symptoms, such as signs of stomach bleeding (e.g., bloody stools, vomiting blood) or severe allergic reactions, require immediate cessation of the drug and medical consultation. For persistent or common side effects that worsen over time, consulting your healthcare provider is also necessary.

Q: Can Sicombyl be taken with common over-the-counter painkillers?

A: Regulatory documents caution against taking Sicombyl with other medications classified as NSAIDs, which include common over-the-counter painkillers like ibuprofen, naproxen, or aspirin. Combining these medicines can increase the risk of serious gastrointestinal side effects, such as bleeding and ulceration.

Q: Are there any foods or drinks I should avoid while taking Sicombyl?

A: Official documents include a specific warning about alcohol (ethanol) use. Using alcohol while taking Sicombyl, especially heavy or daily consumption, increases the risk of gastrointestinal bleeding. No special restrictions are typically listed for non-alcoholic foods or drinks.

Q: Is it normal to feel a little dizzy after starting Sicombyl?

A: Dizziness or vertigo is listed in regulatory documents as a possible adverse effect related to the central nervous system. However, feelings of dizziness can also be a sign of toxicity. If dizziness is concerning or worsens, consultation with a healthcare provider is recommended.

Q: Can Sicombyl cause problems with sleep?

A: Insomnia, or difficulty sleeping, has been reported as an adverse effect in clinical studies associated with the use of salicylate-containing products. While it may not be a core warning, it is documented as a possible central nervous system adverse effect.

Q: Is Sicombyl safe for teenagers to take?

A: Official regulatory warnings advise against using Sicombyl in teenagers and children who have or are recovering from viral illnesses, such as the flu or chickenpox. This is due to the serious, established risk of Reye’s syndrome.

Q: What are the long-term effects of taking Sicombyl?

A: Regulatory documents explicitly state that self-medication should be limited to short periods (e.g., 10 days for pain). Taking the medicine long-term increases the risk of serious adverse effects, including potential gastrointestinal damage and kidney issues. For chronic use, management and monitoring by a healthcare provider are necessary.

Q: Is Sicombyl known to cause any skin rashes or sensitivity?

A: Yes, official safety information states that Sicombyl is contraindicated if a patient has a known hypersensitivity (allergy) to salicylates or other NSAIDs. The drug is also rarely associated with severe cutaneous (skin) adverse reactions.

Q: What is the shelf life of Sicombyl?

A: According to regulatory stability data, the medicine typically has a shelf life of up to three years when stored in its original, sealed packaging. Any solutions prepared by mixing the powder or concentrate generally must be used immediately or within a short, specified period, often 24 hours.

Q: Does Sicombyl make you tired or drowsy?

A: The active ingredient in Sicombyl is not classified as a major sedative. However, central nervous system adverse effects are possible. Patients are advised to be cautious when driving or operating machinery until they know how the medicine affects them.

Q: Will Sicombyl affect my ability to drive or operate machinery?

A: Due to the potential for central nervous system side effects like dizziness or confusion, patients are advised to be cautious when driving or operating machinery until they know how the medicine affects them.

Q: Does Sicombyl interact with herbal supplements?

A: Regulatory guidelines caution against using Sicombyl with other medicines, including supplements, that can affect bleeding or interfere with how the body processes the drug. It is important to discuss all supplements with a healthcare provider, especially those with anti-clotting effects.

Q: Is Sicombyl chemically related to other known drug classes?

A: Yes, regulatory sources classify Sicombyl as a Salicylate Derivative, which is a subclass of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: Can Sicombyl affect mood or cause anxiety?

A: Anxiety has been reported in the medical literature as an occasional adverse reaction to some salicylate-containing products. If changes in mood or anxiety occur after starting the medicine, consulting a doctor is recommended.

Q: Is Sicombyl used for acute issues or long-term management?

A: According to regulatory indications, Sicombyl is used for both. It is prescribed for acute issues like pain and fever over a short duration, and it is also indicated for the long-term management of chronic inflammatory conditions, such as certain types of arthritis.

Q: Why is Sicombyl sometimes given in combination with other medications?

A: Regulatory documents show that Sicombyl is often used as a combination product to pair its analgesic and anti-inflammatory properties with another active ingredient that addresses a different component of the condition, such as a medicine to protect the stomach lining.

Q: How common are severe side effects from Sicombyl?

A: Official warnings categorize the most severe reactions, such as anaphylaxis (a severe allergic reaction), as rare. However, warnings specify that serious events like gastrointestinal bleeding are more common, particularly when high doses are taken or when the user has existing risk factors.

Q: Can Sicombyl be taken with antacids or heartburn medicine?

A: Official documents indicate that antacids may cause the body to eliminate the salicylate more quickly. This may reduce the level of the medicine in the blood and could lessen its effectiveness, especially when taken for its anti-inflammatory benefits.

Q: Why do people sometimes say Sicombyl gives them an upset stomach?

A: Official safety information explicitly warns that Sicombyl is an NSAID and is known to cause gastrointestinal adverse reactions. These effects occur because the medicine can irritate the stomach lining, leading to common symptoms like upset stomach, nausea, or abdominal discomfort.

How should Sicombyl be stored and disposed of?

How to Store and Dispose of Sicombyl?

Sicombyl must be stored at controlled room temperature, typically 25 C (77 F), with permitted brief excursions up to 40 C (104 F). The medicine must be protected from light and moisture and should not be frozen.

Storage and Handling

It is a regulatory requirement to keep the product in a tightly closed container, preferably the original package, and strictly out of the sight and reach of children. If the product is reconstituted or diluted, stability constraints may require that fresh solutions are prepared daily.

Disposal Instructions

Any unused or expired Sicombyl must be disposed of in accordance with local requirements. The product should not be emptied into drains or wastewater to prevent release into the environment, requiring disposal via an approved waste process.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sicombyl found in:

A-Z Index: